drugset / Trial / NCT07444892
Levodopa for Diabetic Retinopathy
Phase 2
Completed
230 enrolled
Emory University
Morningside Center for Innovative and Affordable Medicine · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to determine optimum dosing strategies of levodopa and determine the physiologic mechanisms that provide the therapeutic response to restore abnormalities in the electrical conductivity of the retina in people with diabetes and no clinically visible retinopathy.
Timeline
- Start
- 2022-04-18
- Primary completion
- 2025-11-17
- Completion
- 2025-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levodopa | Small molecule | 100 mg | — |
| Background | Carbidopa | Unknown | 25 mg | — |